Jia-Run Lin, Duan-Duan Han, Wei Wei, Qin Zeng, Zi-Xuan Rong, Xue Bai, Yan-Pei Zhang, Jian Wang, Xiao-Ting Cai, Xu-Guang Rao, Si-Cong Ma, Zhong-Yi Dong
Aspirin has shown potential for cancer prevention, but a recent large randomized controlled trial found no evidence for a reduction in cancer risk. Given the anti-inflammatory effects of aspirin, systemic inflammatory diseases (SIDs), such as osteoporosis, cardiovascular diseases, and metabolic diseases, could potentially modify the aspirin-cancer link. To investigate the impact of aspirin in people with SIDs, we conducted an observational study on a prospective cohort of 478,615 UK Biobank participants. Individuals with at least one of the 41 SIDs displayed a higher cancer risk than those without SIDs...
March 27, 2024: Cancer Research